Free Radicals

Neion Bio is turning chickens into drug factories - Dimi Kellari & Sam Levin

Producing the 3 to 5 grams of a biologic needed for IND-enabling studies costs millions of dollars using traditional CHO manufacturing. A single egg, meanwhile, contains

The golden age for humanity is within our sights - Dr. Derya Unutmaz

Twenty years ago, Dr. Derya Unutmaz predicted we would reverse aging by 2045. People thought he was crazy. Now, he thinks he was too conservative, and has moved the date

Stop optimizing your health and start campaigning against aging - Andrew Steele, Activist & Author

Health podcasts are probably shortening your life expectancy. Not just because of the health anxiety they create, but because that time could instead be spent writing a l

The $101M XPRIZE to restore function by 10 - 20 years - Jamie Justice

Reprogramming molecules are getting dosed into patients for the first time, with the goal of restoring function lost due to aging. I‘ve had over 30 recorded conversations

How DARPA prepares for AI-designed bioweapons & is accelerating progress towards longevity biotech - Dr. Mike Koeris, DARPA Director

AI is accelerating the pace of progress for benevolent scientists and nefarious actors alike. We discuss how DARPA is preparing to defend agriculture & civilians from nov

Replacement & Biostasis: radical approaches for solving aging - Kris Borer, Author & Investor

Kris Borer is an entrepreneur, angel investor, and author of the new book Radical Life Extension. We discuss why Kris rejects incrementalist approaches to radical life e

Selecting the Superman? Embyro selection with Jonathan Anomaly

Jonathan Anomaly is a co-founder of Herasight and former PPE professor. Herasight is pioneering polygenic screening for embryos, to help parents undergoing IVF select emb

The future of AI-powered personalized drugs is only a few years away - Latent Labs founder Simon Kohl

Twelve months ago, we didn’t have working antibody design models. Now we have models that can compress 18 month design timelines down to one month, and agents that can co

How GLP-1s are paving the way for the new era of biotech - Elliot Hershberg, Investor & Blogger

Elliot Hershberg is a partner at Amplify Partners and author of the popular blog Century of Biology. In this episode, we talk about GLP-1s as a breakthrough moment for bi

There are no longevity drugs today, but there will be soon - Dr. James Peyer, Cambrian Founder

Dr. James Peyer is founder and CEO of Cambrian Bio. James has spent two decades working to bring the first longevity drug to market. In this time, he’s brought over $500M

Aging kills EVERYONE, but only because we're not trying hard enough - Longevity Activist Nathan Cheng

Nathan Cheng is an activist who has dedicated his life and career to defeating aging and death. After going through an existential crisis and dropping out of a Physics Ph

The one-man biotech is only 10 years away - a16z-backed founder Kexin Huang

Today’s guest is Kexin Huang. Kexin recently raised $13.5M from Andreessen Horowitz and Menlo Ventures in partnership with Anthropic, to build Phylo - a research lab stud

These 30-something Harvard Professors are making biology programmable - AbuGoot Lab

Two young Harvard professors are coming for the supplements industry. Dr. Jonathan Gootenberg and Dr. Omar Abudayyeh run a joint lab at Harvard Medical School, have co-fo

Longevity politics with the Forbes 30U30 lobbyist changing DC - Dylan Livingston, A4LI

Today’s guest is Dylan Livingston, the 28 year old founder of the Alliance for Longevity Initiatives, known as A4LI. With A4LI, Dylan has created America’s first and only

Ex-BCG leader & David Sinclair’s COO on why evolution selected for aging, and how to get big pharma to invest into longevity therapies - Michael Ringel

Dr. Michael Ringel is a leader in pharma and biotech who spent over 25 years at Boston Consulting Group, where he served as managing director and senior partner, advising

Longevity science & philosophy with the blogger leading theory at Sam Altman’s $1B+ startup - Jose, Author Nintil & Head of Theory at Retro

Jose Luis Ricón Fernández de la Puente is the author of the popular blog Nintil, and Head of Theory at Retro Biosciences. Jose is a prolific blogger, covering a wide brea

Inside the AI used by Sam Altman’s $1B+ longevity startup - Rico Meinl, Head of Applied AI at Retro Bio

Retro Biosciences was seeded with $180M by OpenAI CEO Sam Altman to develop therapies to prevent and reverse age-related disease, and is widely recognized as one of the l

Why DNA Damage is Central to Aging — Christopher Bradley, CEO of Matter Bio

Christopher is a serial entrepreneur who has dedicated himself to solving aging after his last startup Mana Health was acquired by NBC Universal. His company Matter Bio i

The moral and economic case for delaying aging - Raiany Romanni-Klein

Raiany Romanni-Klein is a Harvard and Brown-trained bioethicist focused on understanding why secular people like to narrate death and aging as good things, and quantifyin

Achieving Longevity Escape Velocity with patient avatars — Martin Borch Jensen, CSO of Gordian Biotechnology

Martin Borch Jensen is a scientist, entrepreneur and longevity advocate. He is the co-founder and CSO of Gordian Biotechnology, a company whose platform enables the simul